Nektar Therapeutics (NKTR) Cash from Financing Activities (2010 - 2026)

Nektar Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $529.5 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 7564885.71% year-over-year to $529.5 million in Q1 2026; TTM through Mar 2026 was $710.1 million, a 581955.74% increase from a year earlier, with the FY2025 full-year figure at $180.6 million, up 328.71% from the prior year.
• Cash from Financing Activities advanced to $529.5 million in Q1 2026 per NKTR's latest filing, from $38.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $529.5 million in Q1 2026 and bottomed at $7000.0 in Q1 2025.
• The 5-year median for Cash from Financing Activities is $157000.0 (2022), against an average of $53.8 million.
• Across the five-year window, Cash from Financing Activities plunged 99.98% in 2025 and soared 7564885.71% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $103000.0 in 2022, then slumped by 88.35% to $12000.0 in 2023, then jumped by 591.67% to $83000.0 in 2024, then soared by 46491.57% to $38.7 million in 2025, then jumped by 1269.37% to $529.5 million in 2026.
• Per Business Quant, the three latest NKTR Cash from Financing Activities figures stand at $529.5 million (Q1 2026), $38.7 million (Q4 2025), and $141.7 million (Q3 2025).